French network of cooperative groups in oncology (GCO) at ASCO 2023
9 oral presentations, 7 poster discussions, and 6 posters

The GCO network is a French network of ten cooperative groups conducting clinical and translational research in France and in other countries on solid and liquid tumors (lung, digestive, gynecologic, lymphoma, leukemia, myeloma, head and neck, pediatric and brain cancers…).

They are all not-for-profit organizations and have been accredited as “French cooperative intergroup of international dimension in the field of cancer” by the French National Cancer Institute (INCa).

COLORECTAL AND NON-COLORECTAL CANCERS

GYNECOLOGIC CANCERS

LUNG CANCERS

PEDIATRIC CANCERS

MALIGNANT HEMOPATHIES

COLORECTAL AND NON-COLORECTAL CANCERS

FFCD : Fédération Francophone de Cancérologie Digestive
Francophone Federation of Digestive Tract Cancerology

Poster discussion session
Predictive models of recurrence from transcriptomic signatures of the tumor microenvironment and cell cycle in stage III colon cancer from PETACC-8 and IDEA France trials.

Abstract
Claire Gallois

GERCOR : Groupe Coopérateur Multidisciplinaire en Oncologie
Multidisciplinary Oncology Cooperative Group

Poster session
Assessment of an emergency 14-day (d) integrative supportive care program (14-EISCP) followed by early chemotherapy (CTx) in symptomatic patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): A prospective ARCAD cohort study.

Abstract
Benoit Rousseau
Clinical Science Symposium
An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).

Abstract
Marie Plante

Oral abstract session
In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study.

Abstract
Isabelle Laure Ray-Coquard

Oral abstract session
Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.

Abstract
Philipp Harter

Poster discussion session
Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSO).

Abstract
Susana N. Banerjee

Poster discussion session
Toxicity profile and discordance between patients/physicians regarding niraparib maintenance in recurrent ovarian cancer (ROC) patients: Lessons from the NIQOLE real-life study—GINECO study.

Abstract
Florence Joly

Oral abstract session
Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial.

Abstract
Luc Cabel
**LUNG CANCERS**

**IFCT : Intergroupe Francophone de Cancérologie Thoracique**

*French Cooperative Thoracic Intergroup*

**Oral Abstract Session**

Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.

*Abstract*

Filippo Gustavo Dall'Olio

**Oral abstract session**

IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.

*Abstract*

Quincy S. Chu

**Poster session**

Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.

*Abstract*

Anne-Claire Toffart

**Poster session**

Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.

*Abstract*

Lionel Falchero

**Poster session**

IFCT-2105 lurbincllin real-world effectiveness and treatment sequences in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) who received lurbinectedin as part of the French Early Access Program (EAP-ATU).

*Abstract*

Nicolas Girard

**PEDIATRIC CANCERS**

**SFCE : Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l’adolescent**

*French Society for the Fight against Cancer and Leukemia in Children and Adolescents*

**Poster discussion session**

Comprehensive nationwide study on the prescription of experimental anticancer therapies for compassionate use in children and adolescents in France.

*Abstract*

Pablo Berlanga
MALIGNANT HEMOPATHIES

Poster discussion session
Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.

Abstract
Helen Ajufo

Poster discussion session
Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF).

Abstract
Prithviraj Bose

Poster discussion session
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study.

Abstract
Aaron Thomas Gerds

GRAALL: Group for Research on Adult Acute Lymphoblastic Leukemia.

Poster session
Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3

Abstract
Bijal D. Shah

Oral abstract session
A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.

Abstract
Anthony Selwyn Stein

IFM : Intergroupe francophone du myelome

Poster session
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).

Abstract
Cyrille Touzeau
LYSA : The LYmphoma Study Association

Oral abstract session
Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study

Abstract
Clémentine Sarkozy

More information on the GCO network: www.gco-cancer.org